RE:RE:Pre-FDA approval dealsGleevec was a blockbuster cancer drug for Novartis two decades ago. They need something new. A new class of metal-based drugs like Ruvidar would fit the bill, if TLT opens the kimono wide enough to show them what's going on besides NMIBC. Long shot, but these big pharmas should hopefully like an effective drug that is also 100% safe and easy to manufacture, that too in a niche that's not seen new developments in decades. I still think TLT will need some survival money till BTD. If the AGM agenda says anything about a shareholder vote for a JV, many adults here will cry.